You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

479 Results
Document
Drug
Other Name(s): Oncaspar®
Dec 2022
Guidelines and Advice
Status: Current
Version: 2
May 2021
Regimen
Cancer Type:
Hematologic, 
Lymphoma - T-cell
Intent: Palliative
Funding:
New Drug Funding Program
    Pralatrexate - Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
Jan 2026
Document

Pages